Jim Birchenough
Stock Analyst at Wells Fargo
(2.89)
# 1,406
Out of 5,182 analysts
29
Total ratings
57.89%
Success rate
38.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.20 | +895.02% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $52.06 | +34.46% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $27.94 | +71.80% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.30 | +9,900.00% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $4.02 | +248.26% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $47.14 | +207.59% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $129.26 | -51.26% | 5 | Oct 29, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $18.05 | +210.25% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $731.77 | +0.30% | 2 | May 26, 2020 | |
| KZR Kezar Life Sciences | Maintains: Overweight | $300 → $180 | $7.31 | +2,362.38% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $7.93 | +316.14% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.20
Upside: +895.02%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $52.06
Upside: +34.46%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $27.94
Upside: +71.80%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.30
Upside: +9,900.00%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $4.02
Upside: +248.26%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $47.14
Upside: +207.59%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $129.26
Upside: -51.26%
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $18.05
Upside: +210.25%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $731.77
Upside: +0.30%
Kezar Life Sciences
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $7.31
Upside: +2,362.38%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $7.93
Upside: +316.14%